Anticonvulsants (carbamazepine, valproates, lamotrigine) in bipolar affective disorders;Leki przeciwpadaczkowe (karbamazepina, walproiniany i lamotrygina) w terapii zaburzeń afektywnych dwubiegunowych

Psychiatria Polska

Volumn 36, Issue 6 SUPPL., 2002, Pages 53-61

  Puzyński, Stanisław ^a  

^a II Klinika Psychiatrcyzna IPiN   (Poland)

Author keywords

Anticonvulsants; Bipolar affective disorders

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM CARBONATE; VALPROIC ACID;

AGRANULOCYTOSIS; ARTICLE; ATAXIA; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSARTHRIA; FLU LIKE SYNDROME; HEMATOPOIESIS; HUMAN; HYPOKALEMIA; HYPONATREMIA; LEUKOCYTOSIS; LEUKOPENIA; LIVER FUNCTION; PATIENT COMPLIANCE; RECURRENT DISEASE; SKIN MANIFESTATION; TREATMENT OUTCOME;

ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; PSYCHOTROPIC DRUGS; TRIAZINES; VALPROIC ACID;

EID: 0036965117     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Balfour JA, Bryson H.M. (1994) Valproic acid. A review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs, 2, 144-193.
2. th Ediction, red,: Dukes MNG and Aronson JK, Elsevier Sciences, Amsterdam; str. 164-197.
3. Berȩsewicz M. (2000) Lamotrygina w leczeniu zaburzeń afektywnych, Farmakoterapia w Psychiatrii i Neurologii, 1, 97-101.
4. British National Formulary (BNF), Nr 43 (2002) Brit. Med. Ass. And Royal Pharmaceutical Society London.
5. Calabrese JR, Bowden Ch, Woyshville MJ. (1995) Lithium and the anticonvulsants in the treatment of bipolar disorder. W: Bloom FE, Kupfer DJ (red.): Psychopharmacology: The Fourth Generation of Progress, New York: Raven Press; str. 1099-1111.
6. Davis LL, Ryan W, Adinoff B, Petty F. (2000) Comprehensive review of the psychiatric uses of valproate. J. Clin. Psychopharmacol.; 20, (suppl. 1), 1S-17S.
7. Hebert AA, Ralston JP (2001) Cutaneus reactions to anticonvulsant medications, J. Clin. Psychiatry; 62, suppl. 14, 22-26.
8. Keck PE, McElroy SL. (1998) Antiepileptic drugs. W: Schatzberg AF, Nemeroff C.B. (red.): Textbook of Psychopharmacology. Washington: Amer. Psychiatr. Press; str. 431-454.
9. Lemperiere Th. (2001) Historique du development du valproate dans les troubles bipolaires, L'Encephale; 27, 365-372.
10. Lennkh C, Simhandl C. (2000) Current aspects of valproate in bipolar disorder. Int. Clin. Psychopharmacol.; 15, 1-11.
11. Manji HK, Moore GJ, Chen G (2000) Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic - depressive illness, Biol. Psychiatry; 48, 740-754.
12. Post RM, Rubinow DR, Ballanger JC. (1984) Conditioning sensitization and klindling implications for the course of affective illness. W: Post R.M., Ballanger J.C. (red.): Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins; str. 432-466.
13. Puzyński S. (2001) Pochodne kwasu walproinowego w terapii zaburzeń psychicznych, zwłaszcza chorób afektywnych, Postȩpy Psychiatrii i Neurologii; suppl. 1(13), 25-34.
14. Rzewuska M. (2000) Kwas walproinowy w leczeniu zaburzeń afektywnych, Farmakoterapia w Psychiatrii i Neurologii; 4, 399-416.